Investing in Stem Cells: Stay Away Next Tuesday
By Ian L. Cooper
Sure, 60% of the U.S. supports stem cell research legislation. The legislation passed in the House in January. And it’ll easily pass through the Senate. But the buck will likely stop at Bush’s desk… where he’ll veto it again, just as he did last year.
While I won’t entwine political commentary into investment advice, I will say that the Senate is likely to fall short of the 67 votes needed to override a veto. Just last year, the House and Senate approved the funding bills that were later vetoed by the President. The House then failed to override that veto and the Senate, which did not vote, was also short of the two-thirds vote.
With that in mind, please don’t get swept up buying Aastrom, StemCells Inc, or even Geron, at this point. Your best bet is to buy stem cell stocks, like those mentioned above, as the road to the next White House Administration heats up. And should a pro-stem cell president take over, the sky’s the limit for stem cell stocks.
Investing in Stem Cells: The April 10 Vote
The Senate has scheduled April 10 as its voting day on two stem cell measures. The first measure seeks to mandate federal funding of embryonic stem cell research that would also require the destruction of unborn children for stem cells.
The other – including provisions by Sen. Isaksson (R-Ga.) and sponsored by Coleman (R-Minn.) – seek to fund research on stem cells taken from “dead” embryos, or those embryos taken from living embryos without having to destroy them, according to Congress Daily (as referred to by Medical News Today).
The report continues, “Isakson's provisions would allow federal funding for research on stem cell lines derived from embryos that are not likely to survive during the freezing process or in the womb. According to Isakson, the measure also would promote research using stem cells derived from other sources, such as amniotic fluid. Coleman said the bill might add to the 21 viable stem cell lines currently eligible for federal funding.”
Take care,
Ian L. Cooper, Editor, Early Alert Trader
| |